First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Trial Identifier: TCD17197
Sponsor: Sanofi
Start Date: December 2021
Primary Completion Date: June 2025
Study Completion Date: June 2025
Condition: Leukemia; Heart, Blood & Circulatory - Other; Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
AUSTRALIA, Victoria Melbourne, Victoria, AUSTRALIA, 3004
AUSTRALIA, Victoria Melbourne, Victoria, AUSTRALIA, 3000
CHINA TIANJIN, CHINA, 300020
CHINA ZHENGZHOU, CHINA, 450008
FRANCE MARSEILLE, FRANCE, 13009
FRANCE Paris, FRANCE, 75010
FRANCE PARIS, FRANCE, 75019
FRANCE Villejuif, FRANCE, 94800
NETHERLANDS Amsterdam, NETHERLANDS, 1081 HV
NETHERLANDS Groningen, NETHERLANDS, 9713 GZ
NETHERLANDS NIJMEGEN, NETHERLANDS, 6525 GA
NETHERLANDS Rotterdam, NETHERLANDS, 3015 CE
NETHERLANDS Utrecht, NETHERLANDS, 3584 CS
UNITED STATES, California Duarte, California, UNITED STATES, 91010
UNITED STATES, Georgia Atlanta, Georgia, UNITED STATES, 30303
UNITED STATES, Massachusetts Boston, Massachusetts, UNITED STATES, 02215
UNITED STATES, New York Bronx, New York, UNITED STATES, 10461
UNITED STATES, New York New York, UNITED STATES, 10021
UNITED STATES, Ohio COLUMBUS, Ohio, UNITED STATES, 43210
UNITED STATES, Oregon Portland, Oregon, UNITED STATES, 97239
UNITED STATES, Pennsylvania PHILADELPHIA, Pennsylvania, UNITED STATES, 19104
UNITED STATES, Texas HOUSTON, Texas, UNITED STATES, 77030
UNITED STATES, Washington SEATTLE, Washington, UNITED STATES, 98105